INVESTORS
We operate with trust and do the right thing
News
-
MAR 26 2025News[BioTalkTalk] Interview with Dr. John (Jongsung) Koh, Key Developer of Leclaza at Genosco
-
AUG 20 2024NewsLazertinib With Amivantamab Approved by FDA for Use in NSCLC
-
DEC 22 2023NewsFDA Considers First-Line Amivantamab Plus Lazertinib in EGFR+ NSCLC
-
JUN 30 2023NewsYuhan's Leclaza indication expanded as 1st-line NSCLC treatment
-
DEC 1 2022NewsYuhan’s Leclaza records 20.6-month mPFS as 1st-line NSCLC therapy
-
JUL 26 2022NewsJanssen Announces New Data Supporting Safety and Efficacy of RYBREVANT® and Lazertinib Combination
-
JUN 8 2021NewsHomegrown anticancer drug lazertinib shows expandabilityA follow-up analysis of using Leclaza (ingredient: lazertinib) in combination with Rybrevant (amivantamab) showed that undiscovered biomarkers other than EGFR and MET expression could broaden the group of patients with potential responses
-
MAY 21 2021NewsJohnson & Johnson snares FDA nod for first exon 20-targeted drug in EGFR lung cancerThe regulator on Friday approved Rybrevant for NSCLC patients whose tumors bear exon 20 mutations and have progressed on or after platinum-based chemotherapy...To further secure success, the company is testing the drug alongside lazertinib...
-
FEB 5 2021NewsLeclaza could change Tagrisso-led lung cancer drug marketLeclaza (ingredient: lazertinib), Korea's 31st novel drug that treats lung cancer, has reached the commercialization stage, raising expectations for a new treatment option
